DEA provides opioid shortage updateApril 16, 2018The U.S. Drug Enforcement Administration (DEA) released a statement last week on the ongoing opioid shortages affecting both human and veterinary medicine, resulting from issues at a drug manufacturing plant. "In order to prevent any pharmaceutical drug shortage that negatively impacts patients, DEA is working closely with the U.S. Food and Drug Administration, drug manufacturers, wholesale distributors, and hospital associations to ensure that patients have access to necessary hospital-administered pain medications," said the DEA in its statement. "These include certain injectable products that contain morphine, hydromorphone, meperidine, and fentanyl." "In recent months, the largest U.S. manufacturer of these injectable products has slowed production at one of their manufacturing facilities in order to perform necessary and required upgrades. As a result, this company voluntarily surrendered a portion of their quota allotment and DEA reallocated these amounts to three DEA-registered manufacturers of FDA approved injectable products in accordance with DEA regulations. "DEA is communicating actively and directly with all entities impacted and is committed to making further adjustments to individual procurement quotas as necessary and will also consider other measures that may be necessary to address potential shortages for these products." The shortage is expected to last into …
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
How veterinarians can best manage the opioid shortageMarch 2, 2018Veterinary Practice News organized an exclusive roundtable with five anesthesiologists and pain management experts to discuss the reasons behind the opioid shortage and best practices for identifing solutions to the problem.
